Compound library

Boldenone is a synthetic anabolic steroid approved in the US only as a veterinary medicine for debilitated horses. It has never been approved as a medicine for people.

Drostanolone is a synthetic anabolic steroid that was once used to treat advanced breast cancer in some postmenopausal women. It is no longer an approved medicine in the UK, US or EU.

Metandienone (methandrostenolone) is a synthetic anabolic steroid taken by mouth that was once an approved medicine in the US. It is no longer approved in the UK, US or EU, and is known for its risk of liver injury.

Metenolone is a synthetic anabolic steroid that has been licensed in some countries, including Japan, for conditions such as aplastic anaemia, osteoporosis and severe wasting. It is not an approved medicine in the UK or US.

Nandrolone is a synthetic anabolic steroid made from testosterone. Nandrolone decanoate was approved in the US for anaemia caused by kidney failure, but the original branded products are no longer marketed in the US or UK.

Oxandrolone is a synthetic anabolic steroid taken by mouth. It was approved in the US from 1964, but the FDA withdrew all approvals in 2023 after concluding its risks outweighed unproven benefits.

Stanozolol is a synthetic anabolic steroid derived from testosterone. It was formerly sold as a prescription medicine in the US under the name Winstrol, but it is not a currently licensed human medicine in the UK or US.

Testosterone is the main male sex hormone. Injectable testosterone esters are prescription medicines approved to treat male hypogonadism, where low testosterone has been confirmed by symptoms and blood tests.

Trenbolone is a synthetic anabolic steroid approved only as an ear implant to increase weight gain in beef cattle. It has never been approved as a medicine for people.

Clomifene is a prescription tablet that blocks oestrogen signals in the brain. It is approved to help women who do not ovulate regularly to become pregnant, and is not approved for use in men.

hCG is a hormone made by the placenta that is also produced as a prescription medicine. It is approved for some types of infertility in women, for certain men with low gonadotropin levels, and in the US for undescended testes in boys.

Tamoxifen is a prescription medicine that blocks oestrogen in breast tissue. It is approved to treat hormone-sensitive breast cancer in women and men, and to lower breast cancer risk in some women at high risk.

Anastrozole is a prescription tablet that lowers oestrogen levels by blocking the aromatase enzyme. It is approved to treat hormone receptor-positive breast cancer in women after the menopause.

Cabergoline is a prescription tablet that acts like dopamine to lower prolactin levels. It is approved for high prolactin levels, including prolactin-secreting pituitary tumours. In the UK it is also approved for stopping breast milk production, and in the UK and EU as a second-line treatment for Parkinson's disease.

Exemestane is a prescription tablet that permanently blocks the aromatase enzyme and so lowers oestrogen levels. It is approved to treat oestrogen receptor-positive breast cancer in women after the menopause.

Letrozole is a prescription tablet that lowers oestrogen levels by blocking the aromatase enzyme. It is approved to treat hormone receptor-positive breast cancer in women after the menopause.

Cagrilintide is an experimental long-acting version of the hormone amylin, developed by Novo Nordisk. It is being studied alone and combined with semaglutide (as CagriSema) for obesity and type 2 diabetes, and is not approved anywhere.

Liraglutide is an injected copy of the gut hormone GLP-1 with a shorter action than newer medicines in its class. It is a prescription medicine approved for type 2 diabetes (Victoza) and for weight management in adults and some children with obesity (Saxenda).

Retatrutide is an experimental injected medicine from Eli Lilly that acts on three hormone receptors involved in appetite and metabolism. It is in phase 3 trials for obesity and related conditions and is not approved anywhere.

Semaglutide is a long-acting copy of the gut hormone GLP-1. It is a prescription medicine approved for type 2 diabetes (Ozempic, Rybelsus) and for weight management and cardiovascular risk reduction in people with obesity (Wegovy).

Tirzepatide is a long-acting injected medicine that acts on the receptors for two gut hormones, GIP and GLP-1. It is approved for type 2 diabetes, for weight management in people with obesity, and in the US for obstructive sleep apnoea in adults with obesity.

Bremelanotide is a peptide medicine that acts on melanocortin receptors in the brain. In the US it is approved for premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD).

CJC-1295 is a man-made peptide that copies the action of growth hormone-releasing hormone. It is not approved as a medicine anywhere in the UK, US or EU, and there is little human research on it.

Ipamorelin is a man-made peptide that acts on the ghrelin receptor to trigger growth hormone release. It was tested as a hospital treatment for slow bowel recovery after surgery, but development stopped and it is not approved as a medicine.

Mecasermin is a manufactured form of human insulin-like growth factor 1 (IGF-1). It is approved only to treat poor growth in children with severe primary IGF-1 deficiency, a rare condition.

Somatropin is a manufactured copy of human growth hormone. It is a prescription medicine for children and adults with growth hormone deficiency and for some other conditions that affect growth in children.

Tesamorelin is a man-made version of growth hormone-releasing hormone. In the US it is approved to reduce excess abdominal fat in adults with HIV who have lipodystrophy.